{"id":951,"date":"2012-03-01T12:06:00","date_gmt":"2012-03-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/verordnungen-und-preise-einiger-im-amb-besprochener-arzneimittel-basierend-auf-dem-arzneiverordnungs-report-2011-datenbasis-des-jahres-2010-gkv-arzneimittelindex-im-wido-preisstand-1-maerz-2012"},"modified":"2022-03-17T14:12:21","modified_gmt":"2022-03-17T13:12:21","slug":"verordnungen-und-preise-einiger-im-amb-besprochener-arzneimittel-basierend-auf-dem-arzneiverordnungs-report-2011-datenbasis-des-jahres-2010-gkv-arzneimittelindex-im-wido-preisstand-1-maerz-2012","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/verordnungen-und-preise-einiger-im-amb-besprochener-arzneimittel-basierend-auf-dem-arzneiverordnungs-report-2011-datenbasis-des-jahres-2010-gkv-arzneimittelindex-im-wido-preisstand-1-maerz-2012","title":{"rendered":"Verordnungen und Preise einiger im AMB besprochener Arzneimittel, basierend auf dem Arzneiverordnungs-Report 2011, Datenbasis des Jahres 2010: GKV-Arzneimittelindex im WIdO. Preisstand 1. M\u00e4rz 2012."},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1987,137,73,2403,1903,1906,1267,1036,138,1033,1035,2005,1884,136],"class_list":["post-951","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-adalimumab","tag-antikoagulanzien","tag-clopidogrel","tag-etarnercept","tag-her2","tag-human-epidermal-growth-factor-receptor-2","tag-infliximab","tag-peginterferon-alfa-2a","tag-phenprocoumon","tag-prasugrel","tag-ribavirin","tag-ticagrelor","tag-trastuzumab","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=951"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/951\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}